Adalta Ltd has released a press release.
New malaria inhibiting i-body
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- Chair address and CEO presentation to AGM
- AD-214 Phase I extension clinical study - interim results
- AdAlta closes oversubscribed $1.65 million raise
- Oversubscribed placement result
- Placement to raise up to $1.23million
Later from AdAlta
- January 2024 partnering presentations and progress
- Positive AD-214 Phase I extension study results
- Corporate Presentation
- SYNThesis BioVentures MoU for cellular immunotherapies
- SYNBV MoU Webinar presentation
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta